Volume | 7,639 |
|
|||||
News | - | ||||||
Day High | 2.865 | Low High |
|||||
Day Low | 2.7113 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
AYTU BioPharma Inc | AYTU | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.7113 | 2.7113 | 2.865 | 2.84 | 2.80 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
84 | 7,639 | $ 2.83 | $ 21,628 | - | 1.38 - 3.50 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:35:53 | 50 | $ 2.93 | USD |
AYTU BioPharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
15.81M | 5.57M | - | 107.4M | -17.05M | -3.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
AYTU BioPharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AYTU Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.89 | 2.932 | 2.63 | 2.78 | 7,978 | -0.05 | -1.73% |
1 Month | 3.10 | 3.38 | 2.63 | 3.01 | 16,728 | -0.26 | -8.39% |
3 Months | 2.66 | 3.45 | 2.48 | 3.01 | 21,846 | 0.18 | 6.77% |
6 Months | 2.62 | 3.45 | 2.20 | 2.79 | 28,266 | 0.22 | 8.40% |
1 Year | 2.69 | 3.50 | 1.38 | 2.45 | 73,977 | 0.15 | 5.58% |
3 Years | 136.20 | 144.00 | 1.38 | 30.26 | 489,497 | -133.36 | -97.91% |
5 Years | 40.00 | 235.286 | 1.38 | 34.79 | 2,191,517 | -37.16 | -92.90% |
AYTU BioPharma Description
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. |